Active ingredientSODIUM CITRATE, ANHYDROUS CITRIC ACID
Label structure17 sections
Indications and uses
Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contra...
Dosage and administration
Sodium Citrate and Citric Acid Oral Solution USP should be taken diluted in water, followed by additional water, if desired. SHAKE WELL BEFORE USING.
Storage and handling
Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). Protect from freezing.
Sodium Citrate and Citric Acid Oral Solution USP is a stable and pleasant-tasting systemic alkalizer containing sodium citrate and citric acid in a sugar-free base. It is a nonparticulate neutralizing buffer.
Sodium Citrate and Citric Acid Oral Solution USP contains in each teaspoonful (5 mL):
SODIUM CITRATE Dihydrate 500 mg (0.34 Molar)
CITRIC ACID Monohydrate 334 mg (0.32 Molar)
Each mL contains 1 mEq sodium ion and is equivalent to 1 mEq bicarbonate (HCO3).
Sodium citrate contains the following inactive ingredients: flavoring, polyethylene glycol, propylene glycol, purified water, sodium benzoate, and sorbitol solution.
CLINICAL PHARMACOLOGY
CLINICAL PHARMACOLOGY SECTION
Sodium citrate is absorbed and metabolized to sodium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of sodium citrate is excreted in the urine unchanged.
INDICATIONS AND USAGE
INDICATIONS & USAGE SECTION
Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively.
Sodium Citrate and Citric Acid Oral Solution USP is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods.
CONTRAINDICATIONS
CONTRAINDICATIONS SECTION
Patients on sodium-restricted diets or with severe renal impairment.
PRECAUTIONS
PRECAUTIONS SECTION
Sodium Citrate and Citric Acid Oral Solution USP should be used with caution by patients with low urinary output unless under the supervision of a physician. This product should not be administered concurrently with aluminum-based antacids. Patients should be directed to dilute adequately with water and preferably, to take each dose after meals to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema, and toxemia of pregnancy. Periodic examinations and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.
ADVERSE REACTIONS
ADVERSE REACTIONS SECTION
Sodium Citrate and Citric Acid Oral Solution USP is generally well tolerated, without any unpleasant side effects, when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of alkalosis, especially in the presence of hypocalcemia.
To report SUSPECTED ADVERSE REACTIONS, contact Pharmaceutical Associates, Inc. at 1-800-845-8210 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch..
OVERDOSAGE
OVERDOSAGE SECTION
Overdosage with sodium salts may cause diarrhea, nausea and vomiting, hypernoia, and convulsions.
DOSAGE AND ADMINISTRATION
DOSAGE & ADMINISTRATION SECTION
Sodium Citrate and Citric Acid Oral Solution USP should be taken diluted in water, followed by additional water, if desired. SHAKE WELL BEFORE USING.
For Systemic Alkalization
SPL UNCLASSIFIED SECTION
Usual Adult Dose
SPL UNCLASSIFIED SECTION
2 to 6 teaspoonfuls (10 to 30 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician.
Usual Pediatric Dose
SPL UNCLASSIFIED SECTION
1 to 3 teaspoonfuls (5 to 15 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician. For children under two years of age, use is based on consultation with a physician.
As a neutralizing buffer
SPL UNCLASSIFIED SECTION
3 teaspoonfuls (15 mL), diluted with 15 mL water, taken as a single dose, or as directed by a physician.
HOW SUPPLIED
HOW SUPPLIED SECTION
Sodium Citrate and Citric Acid Oral Solution USP (colorless, grape flavor) is supplied in the following oral dosage forms:
NDC 0121-0595-16: 16 fl oz (473 mL) bottle
NDC 0121-0595-15: 15 mL unit dose cup. Case contains 100 unit-dose cups of 15 mL (NDC 0121-0595-00), packaged in 10 trays of 10 unit-dose cups each.
NDC 0121-1190-30: 30 mL unit dose cup. Case contains 100 unit-dose cups of 30 mL (NDC 0121-1190-00) packaged in 10 trays of 10 unit-dose cups each.
.
STORAGE:
STORAGE AND HANDLING SECTION
Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). Protect from freezing.
SPL UNCLASSIFIED SECTION
Rx ONLY
MANUFACTURED BY:
Pharmaceutical Associates, Inc.
Greenville, SC 29605
www.paipharma.com
R03/22
PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 0121-0595-16
NSN 6505-01-097-4766
Sodium Citrate and Citric Acid Oral Solution USP
500 mg/334 mg per 5 mL
A SUGAR-FREE SYSTEMIC ALKALIZER
Each teaspoonful (5 mL) contains:
Sodium Citrate Dihydrate..........500 mg
Citric Acid Monohydrate............334 mg
Each mL provides 1 mEq Sodium Ion and is
equivalent to 1 mEq Bicarbonate (HCO3).
Rx ONLY
16 fl oz (473 mL)
Pharmaceutical Associates, Inc.
Greenville, SC 29605
473 mL Bottle Label
PRINCIPAL DISPLAY PANEL - 15 mL Unit Dose Cup Label
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Delivers
15 mL
NDC 0121-0595-15
S
ODIUMC
ITRATEand
C
ITRICA
CIDO
RAL S
OLUTIONUSP (Sugar Free)
1.5 g/ 1 g per 15 mL
SHAKE WELL-DILUTE AS DIRECTED
Package Not Child-Resistant
Rx ONLY
PHARMACEUTICAL ASSOCIATES, INC.
GREENVILLE, SC 29605
SEE INSERT
30 mL Unit Dose Cup Label
PRINCIPAL DISPLAY PANEL - 30 mL Unit Dose Cup Label
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Delivers
30 mL
NDC 0121-1190-30
S
ODIUMC
ITRATEand
C
ITRICA
CIDO
RAL S
OLUTIONUSP
(Sugar Free)
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.